Preclinical Evaluation of cRGD‐Functionalized Lipid–Polymer Hybrid Nanocarriers for Anti‐VEGF Gene Therapy in Triple‐Negative Breast Cancer

Busra Cesur Ergun, Devrim Demir‐Dora

Open source

DOI
10.1002/ddr.70402
Published
2026-11
Container
Drug Development Research
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/ddr.70402,
  title = {Preclinical Evaluation of cRGD‐Functionalized Lipid–Polymer Hybrid Nanocarriers for Anti‐VEGF Gene Therapy in Triple‐Negative Breast Cancer},
  author = {Busra Cesur Ergun and Devrim Demir‐Dora},
  year = {2026},
  journal = {Drug Development Research},
  doi = {10.1002/ddr.70402},
  url = {https://doi.org/10.1002/ddr.70402}
}

RIS

TY  - JOUR
TI  - Preclinical Evaluation of cRGD‐Functionalized Lipid–Polymer Hybrid Nanocarriers for Anti‐VEGF Gene Therapy in Triple‐Negative Breast Cancer
AU  - Busra Cesur Ergun
AU  - Devrim Demir‐Dora
PY  - 2026
JO  - Drug Development Research
DO  - 10.1002/ddr.70402
UR  - https://doi.org/10.1002/ddr.70402
ER  - 

APA

Ergun, B. C., & Demir‐Dora, D. (2026). Preclinical Evaluation of cRGD‐Functionalized Lipid–Polymer Hybrid Nanocarriers for Anti‐VEGF Gene Therapy in Triple‐Negative Breast Cancer. Drug Development Research. https://doi.org/10.1002/ddr.70402

Source records